Published in World J Gastroenterol on May 14, 2012
Pharmacokinetic drug interaction profile of omeprazole with adverse consequences and clinical risk management. Ther Clin Risk Manag (2013) 0.96
Evaluation of costs accrued through inadvertent continuation of hospital-initiated proton pump inhibitor therapy for stress ulcer prophylaxis beyond hospital discharge: a retrospective chart review. Ther Clin Risk Manag (2015) 0.80
Brand name and generic proton pump inhibitor prescriptions in the United States: insights from the national ambulatory medical care survey (2006-2010). Gastroenterol Res Pract (2015) 0.80
PA32540 for the secondary prevention of cardiovascular disease in patients at risk for aspirin-associated gastric ulcers. Expert Rev Cardiovasc Ther (2014) 0.75
Use of Proton-Pump Inhibitors Predicts Heart Failure and Death in Patients with Coronary Artery Disease. PLoS One (2017) 0.75
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ (2009) 34.99
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med (2001) 20.20
Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med (2008) 9.25
The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol (1997) 8.88
Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med (2008) 8.39
Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA (2009) 7.78
High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology (2009) 7.40
Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med (2010) 7.39
Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N Engl J Med (2005) 6.39
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA (2010) 6.29
A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ (2009) 6.21
Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol (2008) 5.77
Indications for propensity scores and review of their use in pharmacoepidemiology. Basic Clin Pharmacol Toxicol (2006) 4.70
Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet (2009) 4.31
Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. Arch Intern Med (2000) 3.26
Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome. Circulation (2009) 3.09
Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos (2010) 3.06
Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am Heart J (2008) 3.05
Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos (2004) 3.04
Proton-pump inhibitors are associated with increased cardiovascular risk independent of clopidogrel use: a nationwide cohort study. Ann Intern Med (2010) 2.90
The bias due to incomplete matching. Biometrics (1985) 2.90
Outcomes with concurrent use of clopidogrel and proton-pump inhibitors: a cohort study. Ann Intern Med (2010) 2.90
Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet (2010) 2.72
Performance of propensity score calibration--a simulation study. Am J Epidemiol (2007) 2.56
Adjusting effect estimates for unmeasured confounding with validation data using propensity score calibration. Am J Epidemiol (2005) 2.55
Risk of rehospitalization for patients using clopidogrel with a proton pump inhibitor. Arch Intern Med (2010) 2.04
Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis. J Am Coll Cardiol (2010) 2.03
Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials. Am J Med (2006) 1.76
Effectiveness of national provider prescription of PPI gastroprotection among elderly NSAID users. Am J Gastroenterol (2008) 1.64
Concomitant use of clopidogrel and proton pump inhibitors is not associated with major adverse cardiovascular events following coronary stent implantation. Aliment Pharmacol Ther (2011) 1.58
Cardiovascular and gastrointestinal outcomes in clopidogrel users on proton pump inhibitors: results of a large Dutch cohort study. Am J Gastroenterol (2010) 1.58
Influence of omeprazol on the antiplatelet action of clopidogrel associated to aspirin. J Thromb Haemost (2006) 1.51
Proton pump inhibitors: an update of their clinical use and pharmacokinetics. Eur J Clin Pharmacol (2008) 1.49
Omeprazole, but not pantoprazole, reduces the antiplatelet effect of clopidogrel: a randomized clinical crossover trial in patients after myocardial infarction evaluating the clopidogrel-PPIs drug interaction. Eur J Gastroenterol Hepatol (2011) 1.47
Relation of proton pump inhibitor use after percutaneous coronary intervention with drug-eluting stents to outcomes. Am J Cardiol (2010) 1.47
Review article: the clinical pharmacology of proton pump inhibitors. Aliment Pharmacol Ther (2006) 1.46
Effects of proton pump inhibitors on adverse gastrointestinal events in patients receiving clopidogrel: systematic review and meta-analysis. Drug Saf (2011) 1.45
Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies. Clin Pharmacol Ther (2010) 1.36
Initial assessment of clinical impact of a drug interaction between clopidogrel and proton pump inhibitors. J Am Coll Cardiol (2008) 1.34
Helicobacter pylori increases the risk of upper gastrointestinal bleeding in patients taking low-dose aspirin. Aliment Pharmacol Ther (2002) 1.33
Mortality with upper gastrointestinal bleeding and perforation: effects of time and NSAID use. BMC Gastroenterol (2009) 1.29
ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. Am J Gastroenterol (2010) 1.24
Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose the PACA (Proton Pump Inhibitors And Clopidogrel Association) prospective randomized study. J Am Coll Cardiol (2009) 1.23
Impact of proton pump inhibitors on the effectiveness of clopidogrel after coronary stent placement: the clopidogrel Medco outcomes study. Pharmacotherapy (2010) 1.21
Meta-analysis: the effects of proton pump inhibitors on cardiovascular events and mortality in patients receiving clopidogrel. Aliment Pharmacol Ther (2010) 1.14
Effect of proton pump inhibitors on clinical outcome in patients treated with clopidogrel: a systematic review and meta-analysis. J Thromb Haemost (2010) 1.01
Effect of CYP2C19*2 and *17 mutations on pharmacodynamics and kinetics of proton pump inhibitors in Caucasians. Br J Clin Pharmacol (2008) 1.00
Applying propensity scores estimated in a full cohort to adjust for confounding in subgroup analyses. Pharmacoepidemiol Drug Saf (2011) 1.00
Clinical outcomes in patients with the concomitant use of clopidogrel and proton pump inhibitors after percutaneous coronary intervention: an analysis from the Guthrie Health Off-Label Stent (GHOST) investigators. Circ Cardiovasc Interv (2011) 0.96
Effect of concomitant use of clopidogrel and proton pump inhibitors after percutaneous coronary intervention. Am J Cardiol (2011) 0.96
Risk of adverse outcomes in Taiwan associated with concomitant use of clopidogrel and proton pump inhibitors in patients who received percutaneous coronary intervention. Am J Cardiol (2010) 0.95
The impact of treatment with omeprazole on the effectiveness of clopidogrel drug therapy during the first year after successful coronary stenting. Can J Cardiol (2010) 0.95
Risk of adverse clinical outcomes with concomitant use of clopidogrel and proton pump inhibitors following percutaneous coronary intervention. Dig Dis Sci (2010) 0.94
Pantoprazole does not influence the antiplatelet effect of clopidogrel-a whole blood aggregometry study after coronary stenting. J Cardiovasc Pharmacol (2010) 0.91
Proton pump inhibitors: do differences in pharmacokinetics translate into differences in clinical outcomes? Clin Pharmacokinet (2008) 0.88
Proton pump inhibitors, genetic polymorphisms and response to clopidogrel therapy. Thromb Haemost (2011) 0.86
Drug-drug interaction profiles of proton pump inhibitors. Clin Pharmacokinet (2010) 0.86
Inhibition of the antithrombotic effects of clopidogrel by proton pump inhibitors: facts or fancies? Eur J Intern Med (2010) 0.86
Risk of upper gastrointestinal bleeding associated with non-aspirin cardiovascular drugs, analgesics and nonsteroidal anti-inflammatory drugs. Eur J Gastroenterol Hepatol (2003) 0.86
Clopidogrel and proton pump inhibitors: influence of pharmacological interactions on clinical outcomes and mechanistic explanations. JACC Cardiovasc Interv (2011) 0.85
Pharmacodynamic effects of concomitant versus staggered clopidogrel and omeprazole intake: results of a prospective randomized crossover study. Circ Cardiovasc Interv (2010) 0.84
The potential interaction between clopidogrel and proton pump inhibitors: a systematic review. BMC Med (2010) 0.84
Safety of clopidogrel and proton pump inhibitors in patients undergoing drug-eluting stent implantation. Coron Artery Dis (2011) 0.82
Pharmacodynamic evaluation of pantoprazole therapy on clopidogrel effects: results of a prospective, randomized, crossover study. Circ Cardiovasc Interv (2011) 0.80
Concomitant use of proton pump inhibitors and clopidogrel in patients with coronary, cerebrovascular, or peripheral artery disease in the factores de Riesgo y ENfermedad Arterial (FRENA) registry. J Cardiovasc Pharmacol (2011) 0.80
Clinical evidence of interaction between clopidogrel and proton pump inhibitors. World J Cardiol (2011) 0.79
Recurrence of acute myocardial infarction in patients discharged on clopidogrel and a proton pump inhibitor after stent placement for acute myocardial infarction. Clin Cardiol (2010) 0.78
Randomized double-blind placebo-controlled crossover study to determine the effects of esomeprazole on inhibition of platelet function by clopidogrel. J Thromb Haemost (2011) 0.78
Proton pump inhibitors in patients treated with aspirin and clopidogrel after acute coronary syndrome. Rev Port Cardiol (2010) 0.78
Prescribing proton pump inhibitor and clopidogrel together: current state of recommendations. Curr Opin Gastroenterol (2011) 0.78
Early prediction of acute pancreatitis: prospective study comparing computed tomography scans, Ranson, Glascow, Acute Physiology and Chronic Health Evaluation II scores, and various serum markers. World J Surg (2002) 1.87
Non-alcoholic fatty liver disease in liver transplant recipients: another story of "seed and soil". Am J Gastroenterol (2009) 1.83
Accumulation of hedgehog-responsive progenitors parallels alcoholic liver disease severity in mice and humans. Gastroenterology (2008) 1.71
Chronic parkinsonism associated with cirrhosis: a distinct subset of acquired hepatocerebral degeneration. Arch Neurol (2003) 1.65
Cannabinoid receptor 1 and 2 agonists increase lipid accumulation in hepatocytes. Liver Int (2010) 1.57
Erythromycin intravenous bolus infusion in acute upper gastrointestinal bleeding: a randomized, controlled, double-blind trial. Gastroenterology (2002) 1.57
Risk of complications after abdominal paracentesis in cirrhotic patients: a prospective study. Clin Gastroenterol Hepatol (2009) 1.52
Performance of endosonography-guided fine needle aspiration and biopsy in the diagnosis of pancreatic cystic lesions. Am J Gastroenterol (2003) 1.51
A simple score for predicting alcohol relapse after liver transplantation: results from 387 patients over 15 years. Arch Intern Med (2007) 1.21
An unusual case of gastric heterotopic pancreas. JOP (2004) 1.13
Expression of the bile acid receptor FXR in Barrett's esophagus and enhancement of apoptosis by guggulsterone in vitro. Mol Cancer (2006) 1.07
Role of Toll-like receptor 4 on pancreatic and pulmonary injury in a mice model of acute pancreatitis associated with endotoxemia. Crit Care Med (2004) 0.94
Natural history of long-term lung injury in mouse experimental pancreatitis. Crit Care Med (2002) 0.93
Long-term renal function after liver transplantation is related to calcineurin inhibitors blood levels. Clin Transplant (2006) 0.93
ERCP for gallstone pancreatitis. N Engl J Med (2014) 0.91
Anticoagulant therapy for nodular regenerative hyperplasia in a HIV-infected patient. BMC Gastroenterol (2010) 0.90
Diagnostic criteria in predicting a biliary origin of acute pancreatitis in the era of endoscopic ultrasound: multicentre prospective evaluation of 213 patients. Pancreatology (2005) 0.90
Role of CCL-2, CCR-2 and CCR-4 in cerulein-induced acute pancreatitis and pancreatitis-associated lung injury. J Clin Pathol (2011) 0.89
Fat diet and alcohol-induced steatohepatitis after LPS challenge in mice: role of bioactive TNF and Th1 type cytokines. Cytokine (2008) 0.89
Role of macrophage inflammatory peptide-2 in cerulein-induced acute pancreatitis and pancreatitis-associated lung injury. Lab Invest (2003) 0.87
Conversion to sirolimus-based immunosuppression in maintenance liver transplantation patients. Liver Transpl (2007) 0.85
Image-guided multipolar radiofrequency ablation of liver tumours: initial clinical results. Eur Radiol (2007) 0.85
Multidetector multiphase contrast-enhanced liver CT: prospective study comparing two contrast material injection rates on vascular and liver parenchyma enhancement in patients with varied cirrhotic status. J Comput Assist Tomogr (2006) 0.83
Fibrinogen gamma375 arg-->trp mutation (fibrinogen aguadilla) causes hereditary hypofibrinogenemia, hepatic endoplasmic reticulum storage disease and cirrhosis. Am J Surg Pathol (2006) 0.81
Persistence of mild parkinsonism 4 months after liver transplantation in patients with preoperative minimal hepatic encephalopathy: a study on neuroradiological and blood manganese changes. Transpl Int (2002) 0.81
Unusual Masses of the Pancreas to Be Aware of. Case Rep Gastroenterol (2009) 0.80
Severe immune-mediated drug-induced liver injury linked to ibandronate: a case report. J Hepatol (2013) 0.80
Anticoagulants in portal vein thrombosis: don't be so shy! Blood (2009) 0.80
Liver progenitor cells and therapeutic potential of stem cells in human chronic liver diseases. Acta Gastroenterol Belg (2013) 0.79
Lack of in vivo blockade of Fas- and TNFR1-mediated hepatocyte apoptosis by the hepatitis C virus. J Pathol (2002) 0.79
Phlegmonous colitis: another source of sepsis in cirrhotic patients? BMC Gastroenterol (2009) 0.78
A capillary blood ammonia bedside test following glutamine load to improve the diagnosis of hepatic encephalopathy in cirrhosis. BMC Gastroenterol (2011) 0.78
NK cell isolation from liver biopsies: phenotypic and functional analysis of low cell numbers by flow cytometry. Front Immunol (2013) 0.78
[Child-Pugh, MELD and Maddrey scores]. Rev Med Suisse (2010) 0.77
Pictorial review: rectosigmoid endometriosis on MRI with gel opacification after rectosigmoid colon cleansing. Clin Imaging (2012) 0.77
The role of transient elastography in the detection of liver disease in patients with chronic pancreatitis. Liver Int (2013) 0.76
Concomitant autoimmune and genetic pancreatitis leads to severe inflammatory conditions. World J Gastroenterol (2008) 0.76
Ectopic varices and collaterals development after band ligation treatment in a patient with portal hypertension. Case Rep Gastroenterol (2008) 0.75
Primary aortodigestive fistula: a rare and potentially lethal cause of gastrointestinal hemorrhage. Case Rep Gastroenterol (2011) 0.75
Transjugular intravascular ultrasound for the evaluation of hepatic vasculature and parenchyma in patients with chronic liver disease. BMC Res Notes (2012) 0.75
Age, smoking and overweight contribute to the development of intestinal metaplasia of the cardia. World J Gastroenterol (2012) 0.75
Coincidental CFTR mutation and Sjögren syndrome revealing a pancreatic disease. Pancreas (2007) 0.75
[Hepatic encephalopathy in patients with cirrhosis: new aspects and practical recommendations]. Rev Med Suisse (2010) 0.75
[Management of refractory ascites by the automated low flow pump system (Alfapump)]. Rev Med Suisse (2014) 0.75
[Biliary, pancreatic and systemic diseases associated with IgG4]. Rev Med Suisse (2008) 0.75
[Hereditary haemorrhagic telangiectasia: importance of a multidisciplinary approach]. Rev Med Suisse (2016) 0.75
Acute hepatitis due to brivudin: a case report. J Hepatol (2009) 0.75
[Are non-invasive tests going to replace liver biopsy for diagnosis of liver fibrosis?]. Rev Med Suisse (2012) 0.75
[Management of acute alcoholic steatohepatitis]. Rev Med Suisse (2011) 0.75